Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lia R. Serrano"'
Autor:
Noah M. Lancaster, Pavel Sinitcyn, Patrick Forny, Trenton M. Peters-Clarke, Caroline Fecher, Andrew J. Smith, Evgenia Shishkova, Tabiwang N. Arrey, Anna Pashkova, Margaret Lea Robinson, Nicholas Arp, Jing Fan, Juli Hansen, Andrea Galmozzi, Lia R. Serrano, Julie Rojas, Audrey P. Gasch, Michael S. Westphall, Hamish Stewart, Christian Hock, Eugen Damoc, David J. Pagliarini, Vlad Zabrouskov, Joshua J. Coon
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Owing to its roles in cellular signal transduction, protein phosphorylation plays critical roles in myriad cell processes. That said, detecting and quantifying protein phosphorylation has remained a challenge. We describe the use of a novel
Externí odkaz:
https://doaj.org/article/06a4611f710d4885ae910c3dc977ec18
Autor:
Natalie M. Niemi, Lia R. Serrano, Laura K. Muehlbauer, Catherine E. Balnis, Lianjie Wei, Andrew J. Smith, Keri-Lyn Kozul, Merima Forny, Olivia M. Connor, Edrees H. Rashan, Evgenia Shishkova, Kathryn L. Schueler, Mark P. Keller, Alan D. Attie, Jonathan R. Friedman, Julia K. Pagan, Joshua J. Coon, David J. Pagliarini
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract PPTC7 is a resident mitochondrial phosphatase essential for maintaining proper mitochondrial content and function. Newborn mice lacking Pptc7 exhibit aberrant mitochondrial protein phosphorylation, suffer from a range of metabolic defects, a
Externí odkaz:
https://doaj.org/article/d6347c4096ff4f039a05ff1f1aaf0cd0
Autor:
Vanessa Linke, Edna A. Trujillo, Harold A. Singer, Dain R. Brademan, Deane F. Mosher, Laura K. Muehlbauer, Qiuwen Quan, Evgenia Shishkova, Matthew N. Bernstein, Bradford S Schwartz, Ian J. Miller, Ariel Jaitovich, Jesse G. Meyer, Trenton M. Peters-Clarke, Joshua J. Coon, Scott Swanson, Amit Chopra, Hau Chieng, Brett Paulson, Katherine A. Overmyer, Yunyun Zhu, Joseph Balnis, Anupama Tiwari, Yuchen He, Marc A. Judson, Ron Stewart, Lisa A. Drake, Alejandro P. Adam, Lia R. Serrano
Publikováno v:
Cell Systems
Journal of Translational Medicine
medRxiv
article-version (status) pre
article-version (number) 1
Journal of Translational Medicine
medRxiv
article-version (status) pre
article-version (number) 1
We performed RNA-Seq and high-resolution mass spectrometry on 128 blood samples from COVID-19 positive and negative patients with diverse disease severities and outcomes. Quantified transcripts, proteins, metabolites, and lipids were associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::590b3e958caa102293bf216fffc2d6d4
https://doi.org/10.1101/2020.07.17.20156513
https://doi.org/10.1101/2020.07.17.20156513
Autor:
Terri A. Addona, Christina M. Arieta, Richard B. Gaynor, Dewi Harjanto, Yusuf Nasrullah, Dominik Barthelme, Jeff Hammerbacher, Matthew Malloy, Edward F. Fritsch, Rob C. Oslund, Prerna Suri, Asaf Poran, Joel Greshock, Christopher D. McGann, Daniel A. Rothenberg, Sagar Chhangawala, Scott P. Goulding, Alex Rubinsteyn, Tyler Colson, Gibran Nasir, Amanda L. Creech, Ying S. Ting, Michael S. Rooney, Diana Velez, Jennifer G. Abelin, Lia R. Serrano
Publikováno v:
Immunity. 51(4)
Summary Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and control tumor growth. However, it remains difficult to predict the antigens that will be presented by human leukocyte antigen class II molecules (HLA-II), h
Autor:
Rob C. Oslund, Dewi Harjanto, Jennifer G. Abelin, Jeff Hammerbacher, Yusuf Nasrullah, Sagar Chhangawala, Lia R. Serrano, Alex Rubinsteyn, Gibbs Nasir, Amanda L. Creech, Ying S. Ting, Christopher D. McGann, Asaf Poran, Edward F. Fritsch, Michael S. Rooney, Tyler Colson, Dominik Barthelme, Daniel A. Rothenberg, Scott P. Goulding, Prerna Suri, Terri A. Addona, Matthew Malloy, Christina M. Arieta, Richard B. Gaynor, Diana Velez
Publikováno v:
Cancer Immunology Research. 8:B23-B23
While tumor-reactive CD4+ T cells have been associated with effective immunotherapy responses, accurate prediction of MHC class II-restricted ligands remains a challenge, limiting our ability to harness CD4+ immunity for cancer therapy. To this end,